Drug–Antacid Interaction With Amphetamine Stimulants
Coadministration of magnesium oxide (a GI alkalinizing antacid) with lisdexamfetamine (Elvanse/Vyvanse) or dexamfetamine/dextroamphetamine (e.g., Amfexa) can increase systemic amphetamine exposure and thereby increase the risk of stimulant adverse effects. [1] [2]
Pharmacokinetic Implications
GI alkalinizing agents (including GI antacids) increase blood levels of amphetamine. [2]
Acidifying agents decrease blood levels of amphetamine. [1]
Magnesium oxide acts as an antacid and can produce GI alkalinization, which is pharmacokinetically consistent with increased amphetamine blood levels when taken with amphetamine stimulants. [3] [2]
Safety Implications
Increased amphetamine exposure increases the likelihood of sympathomimetic adverse effects that are concentration-dependent (e.g., tachycardia, increased blood pressure, insomnia, anxiety, appetite loss). [1] [4]
Because GI antacids are specifically described as alkalinizing agents that increase amphetamine blood levels, concurrent use with magnesium oxide increases the risk of stimulant adverse effects. [2]
Efficacy Implications
Magnesium oxide may increase amphetamine blood levels through GI alkalinization. [2]
No guideline-grade evidence supports a consistent efficacy improvement from routine coadministration. [1]
Increased exposure can present clinically as stronger or prolonged stimulant effects, which is a safety rather than an efficacy advantage. [2]
Recommendation on Co-administration
Concurrent use is not recommended. Gastrointestinal alkalinizing agents “such as antacids” are described as requiring avoidance with amphetamine formulations due to increased absorption/blood levels. [5]
A safer approach is avoiding administration at the same time and using a separation-of-dosing strategy when antacids are required. [1] [5]
Practical Monitoring and Adjustment Considerations
If magnesium oxide is used despite interaction concerns, stimulant adverse effects should be monitored closely, including vital sign changes and CNS effects. [1] [4]
If symptoms consistent with excess stimulant exposure occur after antacid initiation, clinicians should consider stopping or separating magnesium oxide rather than escalating stimulant dose. [2] [1]
Key Bottom-Line Safety/PK Takeaway
Magnesium oxide should be treated as a GI alkalinizing antacid. [3]
Coadministration with lisdexamfetamine or dexamfetamine is expected to increase amphetamine blood levels and therefore increase risk of stimulant adverse effects. [1] [2]